The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Medicinal Chemistry

Topics

Biochemistry

Biology

Biochemistry

Chemistry

Genetics

Pharmacology

Show all topics

DOI

10.1021/jm800295d